Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.

other branded AHAs cohort, although the difference in inpatient costs did not reach statistical significance (Fig. 3 ).

also in 111,027 other papers

Results from that study showed a trend toward lower inpatient and outpatient costs and significantly lower HCRU among patients initiating empagliflozin compared to DPP4i.

also in 53,322 other papers